IGT Type2 diabetes
Conditions
Interventions
beta-cryptoxanthin containing beverages
placebo
Sponsors
Brain/Liver Interface Medicine Research Center, Japan
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Impaired glucose tolerance patients and patients with type 2 diabetes 2.purpose education hospitalization 3.Patient capable of glycemic control 4.FPG <400mg/dl on admission and FPG <150 mg / dl at the start of the test
Exclusion criteria
Exclusion criteria: 1.history of type 1 diabetes or history of ketoacidosis 2.history of hypoglycemia severe symptoms associated with loss of consciousness or coma 3.severe infection, the severe trauma 4. poorly controlled hypertension, systolic blood pressure >160 mmHg, or diastolic blood pressure >100 5.patients with grade 3 or more of the Ministry of Health, Labour and Welfare drug side effects classification serious complication 6.pregnancy or breast feeding 7.inability to participate in the study as assessed by the investigators
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood glucose fluctuation M values, MAGE, and blood glucose standard deviation were calculated from CGM | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.Changes in the physical findings(Body weight/waist circumference/Blood pressure/ Heart rate/The body composition by impedance method) 2.Evaluation of verification and safety of adverse events (hypoglycemia, hyperglycemia, gastrointestinal symptoms) 3.Factors associated with effect of glucose metabolism | — |
Countries
Japan
Contacts
Public ContactTsuguhito Ota
Kanazawa University Hospital Department of Medicine
Outcome results
None listed